Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Oct 1;18(19):5160-2.
doi: 10.1158/1078-0432.CCR-12-2408. Epub 2012 Aug 21.

The promise of patient-derived xenografts: the best laid plans of mice and men

Scott Kopetz  1 , Robert Lemos, Garth Powis
Affiliations
Comment

The promise of patient-derived xenografts: the best laid plans of mice and men

Scott Kopetz et al. Clin Cancer Res. .

Abstract

Compared with xenografts from previously established cell lines, patient-derived xenografts may more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumors, although other limitations of murine models remain. The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None of relevance

Figures

Figure
Figure
Cell line based models have been criticized for their poor ability to predict outcomes for advanced cancer patients(3). Patient-derived xenografts have several characteristics that better recapitulate the clinical reality for patients. This tumor model “abacus” highlights areas of strength and weakness of patient-derived xenografts compared the cell line and human models. Blue squares further to the right represent positive characteristics of the patient-derived xenografts that are closer to the tumor biology of the patient.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Can Res. [Epub ahead of print] - PubMed
    1. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–1680. - PMC - PubMed
    1. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med. 2010;16:974–975. - PubMed
    1. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004;40:298–307. - PubMed
    1. Carney DN, Winkler CF. In vitro assays of chemotherapeutic sensitivity. Important Adv Oncol. 1985:78–103. - PubMed

Publication types